An analysis of the resource use and costs of febrile neutropenia events in pediatric cancer patients in Australia

• Published in: Pediatric blood & cancer Vol. 70; no. 11; p. e30633
• Main Authors: Vargas, Constanza, Haeusler, Gabrielle M, Slavin, Monica A, Babl, Franz E, Mechinaud, Francoise, Phillips, Robert, Thursky, Karin, Lourenco, Richard De Abreu
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01-11-2023
• Subjects: Aged; Antimicrobial agents; Antineoplastic Agents - therapeutic use; Australia; Cancer; Child; Febrile Neutropenia - drug therapy; Health care; Hematology; Hospital costs; Humans; National Health Programs; Neoplasms - complications; Neoplasms - drug therapy; Neutropenia; Oncology; Patients; Pediatrics; Sepsis; Australia; costs; febrile neutropenia; pediatric cancer
• ISSN: 1545-5009; 1545-5017
• DOI: 10.1002/pbc.30633

Febrile neutropenia (FN) in children with cancer generally requires in-hospital care, but low-risk patients may be successfully managed in an outpatient setting, potentially reducing the overall healthcare costs. Updated data on the costs of FN care are lacking.
A bottom-up microcosting analysis was conducted from the healthcare system perspective using data collected alongside the Australian PICNICC (Predicting Infectious Complications of Neutropenic sepsis In Children with Cancer) study. Inpatient costs were accessed from hospital administrative records and outpatient costs from Medicare data. Costs were stratified by risk status (low/high risk) according to the PICNICC criteria. Estimated mean costs were obtained through bootstrapping and using a linear model to account for multiple events across individuals and other clinical factors that may impact costs.
The total costs of FN care were significantly higher for FN events classified as high-risk ($17,827, 95% confidence interval [CI]: $17,193-$18,461) compared to low-risk ($10,574, 95% CI: $9818-$11,330). In-hospital costs were significantly higher for high-risk compared to low-risk events, despite no differences in the cost structure, mean cost per day, and pattern of resource use. Hospital length of stay (LOS) was the only modifiable factor significantly associated with total costs of care. Excluding antineoplastics, antimicrobials are the most commonly used medications in the inpatient and outpatient setting for the overall period of analysis.
The FN costs are driven by in-hospital admission and LOS. This suggests that the outpatient management of low-risk patients is likely to reduce the in-hospital cost of treating an FN event. Further research will determine if shifting the cost to the outpatient setting remains cost-effective overall.